

Description

Field of the invention

This invention relates generally to new hybrid cell lines and more specifically to hybrid cell lines for production of monoclonal antibody to an antigen found on essentially all normal human peripheral T cells and on approximately 95% of normal human thymocytes, to the antibody so produced, to diagnostic methods and to therapeutic and diagnostic compositions employing this antibody.

Description of the prior art

The fusion of mouse myeloma cells to spleen cells from immunized mice by Kohler and Milstein in 1975 [*Nature* 256, 495—497 (1975)] demonstrated for the first time that it was possible to obtain a continuous cell line making homogeneous (so-called "monoclonal") antibody. Since this seminal work, much effort has been directed to the production of various hybrid cells (called "hybridomas") and to the use of the antibody made by these hybridomas for various scientific investigations. See, for example, *Current Topics in Microbiology and Immunology*, Volume 81—"Lymphocyte Hybridomas", F. Melchers, M. Potter, and N. Warner, Editors, Springer-Verlag, 1978, and references contained therein; C. J. Barnstable, et al., *Cell*, 14, 9—20 (May, 1978); P. Parham and W. F. Bodmer, *Nature* 276, 397—399 (November, 1978); *Handbook of Experimental Immunology*, Third Edition, Volume 2, D. M. Wier, Editor, Blackwell, 1978, Chapter 25; and *Chemical and Engineering News*, January 1, 1979, 15—17. These references simultaneously indicate the rewards and complications of attempting to produce monoclonal antibody from hybridomas. While the general technique is well understood conceptually, there are many difficulties met and variations required for each specific case. In fact, there is no assurance, prior to attempting to prepare a given hybridoma, that the desired hybridoma will be obtained, that it will produce antibody if obtained, or that the antibody so produced will have the desired specificity. The degree of success is influenced principally by the type of antigen employed and the selection technique used for isolating the desired hybridoma.

The attempted production of monoclonal antibody to human lymphocyte cell-surface antigens has been reported only in a few instances. See, for example, *Current Topics in Microbiology and Immunology*, *ibid*, 66—69 and 164—169. The antigens used in these reported experiments were cultured human lymphoblastoid leukemia and human chronic lymphocytic leukemia cell lines. Many hybridomas obtained appeared to produce antibody to various antigens on all human cells. None of the hybridomas produced antibody against a predefined class of human lymphocytes.

More recently, the present applicants and others have authored articles disclosing the preparation and testing of hybridomas making antibody to certain T-cell antigens. See, for example, Reinherz, E. L., et al., *J. Immunol.* 123, 1312—1317 (1979); Reinherz, E. L., et al., *Proc. Natl. Acad. Sci.*, 76, 4061—4065 (1979); and Kung, P. C., et al., *Science*, 206, 347—349 (1979).

It should be understood that there are two principal classes of lymphocytes involved in the immune system of humans and animals. The first of these (the thymus-derived cell or T cell) is differentiated in the thymus from haemopoietic stem cells. While within the thymus, the differentiating cells are termed "thymocytes". The mature T cells emerge from the thymus and circulate between the tissues, lymphatics, and the bloodstream. These T cells form a large proportion of the pool of recirculating small lymphocytes. They have immunological specificity and are directly involved in cell-mediated immune responses (such as graft rejection) as effector cells. Although T cells do not secrete humoral antibodies, they are sometimes required for the secretion of these antibodies by the second class of lymphocytes discussed below. Some types of T cells play a regulating function in other aspects of the immune system. The mechanism of this process of cell cooperation is not yet completely understood.

The second class of lymphocytes (the bone marrow-derived cells or B cells) are those which secrete antibody. They also develop from haemopoietic stem cells, but their differentiation is not determined by the thymus. In birds, they are differentiated in an organ analogous to the thymus, called the Bursa of Fabricius. In mammals, however, no equivalent organ has been discovered, and it is thought that these B cells differentiate within the bone marrow.

It is now recognized that T cells are divided into at least several subtypes, termed "helper", "suppressor", and "killer" T cells, which have the function of (respectively) promoting a reaction, suppressing a reaction, or killing (lysing) foreign cells. These subclasses are well understood for murine systems, but they have only recently been described for human systems. See, for example, R. L. Evans, et al., *Journal of Experimental Medicine*, Volume 145, 221—232, 1977; and L. Chess and S. F. Schlossman—"Functional Analysis of Distinct Human T-Cell Subsets Bearing Unique Differentiation Antigens", in *"Contemporary Topics in Immunobiology"*, O. Stutman, Editor, Plenum Press, 1977, Volume 7, 363—379.

The ability to identify or suppress classes or subclasses of T cells is important for diagnosis or treatment of various immunoregulatory disorders or conditions.

For example, certain leukemias and lymphomas have differing prognosis depending on whether they are of B cell or T cell origin. Thus, evaluation of the disease prognosis depends upon distinguishing between these two classes of lymphocytes. See, for example, A. C. Aisenberg and J. C. Long, *The American Journal of Medicine*, 58:300 (March, 1975); D. Belpomme, et al., in *"Immunological Diagnosis of Leukemias*

and Lymphomas", S. Thierfelder, *et al.*, eds, Springer, Heidelberg, 1977, 33—45; and D. Belpomme, *et al.*, *British Journal of Haematology*, 1978, 38, 85.

Certain disease states (e.g., juvenile rheumatoid arthritis, malignancies, and agammaglobulinemia) are associated with an imbalance of T cell subclasses. It has been suggested that autoimmune diseases generally are associated with an excess of "helper" T cells or a deficiency of certain "suppressor" T cells, while agammaglobulinemia is associated with an excess of certain "suppressor" T cells or a deficiency of "helper" T cells. Malignancies generally are associated with an excess of "suppressor" T cells.

In certain leukemias, excess T cells are produced in an arrested stage of development. Diagnosis may thus depend on the ability to detect this imbalance or excess and to determine which developmental stage is in excess. See, for example, J. Kersey, *et al.*, "Surface Markers Define Human Lymphoid Malignancies with Differing Prognoses" in *Haematology and Blood Transfusion*, Volume 20, Springer—Verlag, 1977, 17—24, and references contained therein; and E. L. Reinherz, *et al.*, *J. Clin. Invest.*, 64, 392—397 (1979).

Acquired agammaglobulinemias, a disease state in which no immuneoglobulin is produced, comprises at least two distinct types. In type I the failure to produce immunoglobulin is due to an excess of suppressor T cells, while in type II it is due to a lack of helper T cells. In both types, there appears to be no defect or lack in the patient's B cells, the lymphocytes which are responsible for the actual secretion of the antibody; however, these B cells are being either suppressed or "not helped", resulting in greatly decreased or absent immunoglobulin production. The type of acquired agammaglobulinemia may thus be determined by testing for an excess of suppressor T cells or an absence of helper T cells.

On the therapeutic side, there is some suggestion, as yet not definitely proven, that administration of antibodies against the subtype of T cell in excess may have therapeutic benefit in autoimmune disease or malignancies. For example, a helper T cell cancer (certain cutaneous T cell lymphomas and certain T cell acute lymphoblastic leukemias) may be treated by an antibody to a helper T cell antigen. Treatment of autoimmune disease caused by an excess of helper cells may also be accomplished in the same fashion.

Treatment of diseases (e.g., malignancies or type I acquired agammaglobulinemia) due to an excess of suppressor T cells may be treated by administration of an antibody to a suppressor T cell antigen.

Antisera against the entire class of human T cells (so-called antihuman thymocyte globulin or ATG) has been reported useful therapeutically in patients receiving organ transplants. Since the cell-mediated immune response (the mechanism whereby transplants are rejected) depends upon T cells, administration of antibody to T cells prevents or retards this rejection process. See, for example, Cosimi, *et al.*, "Randomized Clinical Trial of ATG in Cadaver Renal Allograft Recipients: Importance of T Cell Monitoring", *Surgery* 40:155—163 (1976) and references contained therein; and Wechter, *et al.*, "Manufacture of Antithymocyte Globulin for Clinical Trials", *Transplantation*, 28 (4), 303—307 (1979).

The identification and suppression of human T cell classes and subclasses has previously been accomplished by the use of spontaneous autoantibodies or selective antisera for human T cells obtained by immunizing animals with human T cells, bleeding the animals to obtain serum, and absorbing the antiserum with (for example) autologous but not allogeneic B cells to remove antibodies with unwanted reactivities. The preparation of these antisera is extremely difficult, particularly in the adsorption and purification steps. Even the adsorbed and purified antisera contain many impurities in addition to the desired antibody, for several reasons. First, the serum contains millions of antibody molecules even before the T cell immunization. Second, the immunization causes production of antibodies against a variety of antigens found on all human T cells injected. There is no selective production of antibody against a single antigen. Third, the titer of specific antibody obtained by such methods is usually quite low, (e.g., inactive at dilutions greater than 1:100) and the ratio of specific to non-specific antibody is less than 1/10⁶.

See, for example, the Chess and Schlossman article referred to above (at pages 365 and following) and the Chemical and Engineering News article referred to above, where the deficiencies of prior art antisera and the advantages of monoclonal antibody are described.

Summary of invention

There has now been discovered a novel hybridoma (designated OKT11) which is capable of producing novel monoclonal antibody against an antigen found on essentially all normal human peripheral T cells and on approximately 95% of normal human thymocytes, but not on normal human B cells or null cells.

The antibody so produced is monospecific for a single determinant on essentially all normal human peripheral T cells and contains essentially no other anti-human immunoglobulin, in contrast to prior art antisera (which are inherently contaminated with antibody reactive to numerous human antigens) and to prior art monoclonal antibodies (which are not monospecific for a human T cell and thymocyte antigen). Moreover, this hybridoma can be cultured to produce antibody without the necessity of immunizing and killing animals, followed by the tedious adsorption and purification steps necessary to obtain even the impure antisera of the prior art.

It is accordingly one object of this invention to provide hybridomas which produce antibodies against an antigen found on essentially all of normal human peripheral T cells.

It is a further aspect of the present invention to provide methods for preparing these hybridomas.

A further object of the invention is to provide essentially homogeneous antibody against an antigen found on essentially all normal human peripheral T cells.

A still further object is to provide methods for diagnosis of disease employing this antibody.

(11)

Other objects and advantages of the invention will become apparent from the examination of the present disclosure.

In satisfaction of the foregoing objects and advantages, there is provided by this invention a novel hybridoma producing novel antibody to an antigen found on essentially all normal human peripheral T cells and on approximately 95% of normal human thymocytes (but not on normal human B cells or null cells), the antibody itself, and diagnostic methods employing the antibody. The hybridoma was prepared generally following the method of Milstein and Köhler. Following immunization of mice with leukemic cells from a human with T-cell acute lymphoblastic leukemia (T-ALL), the spleen cells of the immunized mice were fused with cells from a mouse myeloma line and the resultant hybridomas screened for those with supernatants containing antibody which gave selective binding to normal E rosette positive human T cells and/or E⁻ human cells. The desired hybridomas were subsequently cloned and characterized. As a result, a hybridoma was obtained which produces antibody (designated OKT11) against an antigen on essentially all normal human peripheral T cells. Not only does this antibody react with essentially all normal human peripheral T cells, but it also reacts with about 95% of normal human thymocytes but does not react with normal human B cells or null cells.

In view of the difficulties indicated in the prior art and the lack of success reported using malignant cell lines as the antigen, it was surprising that the present method provided the desired hybridoma. It should be emphasized that the unpredictable nature of hybrid cell preparation does not allow one to extrapolate from one antigen or cell system to another. In fact, the present applicants have discovered that the use of a T cell malignant cell line or purified antigens separated from the cell surface as the antigen were generally unsuccessful.

Both the subject hybridoma and the antibody produced thereby are identified herein by the designation "OKT11", the particular material referred to being apparent from the context. The subject hybridoma was deposited on December 13, 1979 at the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852, and was given the ATCC accession number CRL 8027.

According to the present invention there is provided mouse monoclonal antibody which:

- i) reacts with essentially all normal human peripheral T cells;
- ii) reacts with approximately 95% of normal human thymocytes; and
- iii) does not react with any of the normal human cells in the group comprising B cells and Null cells, and which preferably is of class IgG.

Preferably, the antibody exhibits the pattern of reactivity to normal human thymocytes, E⁺, and E⁻ cells shown in Figure 1. The antibody preferably also exhibits the pattern of reactivity to T lineage lymphocyte phenocytes as shown in Table 1. Advantageously, the antibody defines a T cell population (OKT11⁺) which is lower than normal levels in myasthenia gravis and multiple sclerosis; higher than normal levels in acute graft versus host reaction, hyper IgE, acute infectious mononucleosis, and primary biliary cirrhosis; and completely absent in all stages of Hodgkins disease and psoriasis.

Conveniently, the antibody is produced by a hybridoma formed by fusion of cells from a mouse myeloma line and spleen cells from a mouse previously immunised with leukemic cells from a human with T-ALL.

Preferably, the antibody is produced by hybridoma ATCC CRL 8027 (OKT11).

The present invention also provides a hybridoma, for producing antibody according to the invention, formed by fusion of spleen cells from a mouse previously immunized with leukemic cells from a human with T-ALL and cells from a mouse myeloma line.

Preferably the hybridoma is ATCC CRL 8027 (OKT11).

According to a further aspect of the present invention, there is provided a method for preparing an antibody according to the invention, which comprises the steps of:

- i) immunizing mice with human leukemic T-ALL cells;
- ii) removing the spleens from said mice and making a suspension of spleen cells;
- iii) fusing said spleen cells with mouse myeloma cells in the presence of a fusion promoter;
- iv) diluting and culturing the fused cells in separate wells in a medium which will not support the unfused myeloma cells;
- v) evaluating the supernatant in each well containing a hybridoma for the presence of an antibody having any of the properties specified above;
- vi) selecting and cloning hybridomas producing the desired antibody; and
- vii) recovering the antibody from the supernatant above said clones.

Alternatively, the selected hybridoma is transferred intraperitoneally to a mouse and the antibody is harvested from the malignant ascites or serum of said mouse.

In another aspect, the invention provides a method for preparing a mouse monoclonal antibody, which comprises culturing the hybridoma ATCC CRL 8027 in a suitable medium and recovering the antibody from the supernatant above said hybridoma.

Alternatively, the method comprises injecting into a mouse the hybridoma ATCC CRL 8027 and recovering the antibody from the malignant ascites or serum of said mouse.

The preparation and characterization of the hybridoma and the resultant antibody will be better understood by reference to the following description and Examples.

Detailed description of the invention

The method of preparing the hybridoma generally comprises the following steps:

A. Immunizing mice with leukemic cells from a human with T-ALL. While it has been found that female CAF₁ mice are preferred, it is contemplated that other mouse strains could be used. The immunization schedule and thymocyte concentration should be such as to produce useful quantities of suitably primed splenocytes. Three immunizations at fourteen day intervals with 2×10^7 cells/mouse/injection in 0.2 ml phosphate buffered saline has been found to be effective.

B. Removing the spleens from the immunized mice and making a spleen suspension in an appropriate medium. About one ml of medium per spleen is sufficient. These experimental techniques are well-known.

C. Fusing the suspended spleen cells with mouse myeloma cells from a suitable cell line by the use of a suitable fusion promoter. The preferred ratio is about 5 spleen cells per myeloma cell. A total volume of about 0.5—1.0 ml of fusion medium is appropriate for about 10^8 splenocytes. Many mouse myeloma cell lines are known and available, generally from members of the academic community or various deposit banks, such as the Salk Institute Cell Distribution Center, La Jolla, CA. The cell line used should preferably be of the so-called "drug resistant" type, so that unfused myeloma cells will not survive in a selective medium, while hybrids will survive. The most common class is 8-azaguanine resistant cell lines, which lack the enzyme hypoxanthine guanine phosphoribosyl transferase and hence will not be supported by HAT (hypoxanthine, aminopterin, and thymidine) medium. It is also generally preferred that the myeloma cell line used be of the so-called "non-secreting" type, in that it does not itself produce any antibody, although secreting types may be used. In certain cases, however, secreting myeloma lines may be preferred. While the preferred fusion promoter is polyethylene glycol having an average molecular weight from about 1000 to about 4000 (commercially available as PEG 1000, etc.), other fusion promoters known in the art may be employed.

D. Diluting and culturing in separate containers, the mixture of unfused spleen cells, unfused myeloma cells, and fused cells in a selective medium which will not support the unfused myeloma cells for a time sufficient to allow death of the unfused cells (about one week). The dilution may be a type of limiting one, in which the volume of diluent is statistically calculated to isolate a certain number of cells (e.g., 1—4) in each separate container (e.g., each well of a microtiter plate). The medium is one (e.g., HAT medium) which will not support the drug resistant (e.g., 8-azaguanine resistant) unfused myeloma cell line. Hence, these myeloma cells perish. Since the unfused spleen cells are non-malignant, they have only a finite number of generations. Thus, after a certain period of time (about one week) these unfused spleen cells fail to reproduce. The fused cells, on the other hand, continue to reproduce because they possess the malignant quality of the myeloma parent and the ability to survive in the selective medium of the spleen cell parent.

E. Evaluating the supernatant in each container (well) containing a hybridoma for the presence of antibody to E rosette positive purified human T cells or thymocytes.

F. Selecting (e.g., by limiting dilution) and cloning hybridomas producing the desired antibody.

Once the desired hybridoma has been selected and cloned, the resultant antibody may be produced in one of two ways. The purest monoclonal antibody is produced by *in vitro* culturing of the desired hybridoma in a suitable medium for a suitable length of time, followed by recovery of the desired antibody from the supernatant. The suitable medium and suitable length of culturing time are known or are readily determined. This *in vitro* technique produces essentially monospecific monoclonal antibody, essentially free from other specific antihuman immunoglobulin. There is a small amount of other immunoglobulin present since the medium contains xenogeneic serum (e.g., fetal calf serum). However, this *in vitro* method may not produce a sufficient quantity or concentration of antibody for some purposes, since the concentration of monoclonal antibody is only about 50 µg/ml.

To produce a much greater concentration of slightly less pure monoclonal antibody, the desired hybridoma may be injected into mice, preferably syngenic or semi-syngenic mice. The hybridoma will cause formation of antibody-producing tumors after a suitable incubation time, which will result in a high concentration of the desired antibody (about 5—20 mg/ml) in the bloodstream and peritoneal exudate (ascites) of the host mouse. Although these host mice have normal antibodies in their blood and ascites, the concentration of these normal antibodies is only about 5% of the monoclonal antibody concentration. Moreover, since these normal antibodies are not antihuman in their specificity, the monoclonal antibody obtained from the harvested ascites or from the serum is essentially free of any contaminating antihuman immunoglobulin. This monoclonal antibody is high titer (active at dilutions of 1:50,000 or higher) and high ratio of specific to non-specific immunoglobulin (about 1/20). Immunoglobulin produced incorporating the light myeloma chains are non-specific, "nonsense" peptides which merely dilute the monoclonal antibody without detracting from its specificity.

Example I

60 Production of monoclonal antibodies

A. Immunization and somatic cell hybridization

Female CAF₁ mice (Jackson Laboratories; 6—8 weeks old) were immunized intraperitoneally with 2×10^7 human leukemic T-ALL cells in 0.2 ml of phosphate buffered saline at 14-day intervals. Four days after the third immunization, spleens were removed from the mice, and a single cell suspension was made by pressing the tissue through a stainless steel mesh.

Cell fusion was carried out according to the procedure developed by Kohler and Milstein. 1×10^6 splenocytes were fused in 0.5 ml of a fusion medium comprising 35% polyethylene glycol (PEG 1000) and 5% dimethylsulfoxide in RPMI 1640 medium (Gibco, Grand Island, NY) with 2×10^7 P3X63Ag8U1 myeloma cells supplied by Dr. M. Schärff, Albert Einstein College of Medicine, Bronx, NY. These myeloma cells secrete IgG₁ light chains.

B. Selection and growth of hybridoma

After cell fusion, cells were cultured in HAT medium (hypoxanthine, aminopterin, and thymidine) at 37°C with 5% CO₂ in a humid atmosphere. Several weeks later, 40 to 100 l of supernatant from cultures containing hybridomas were added to a pellet of 10^8 peripheral lymphocytes separated into E rosette positive (E⁺) and E rosette negative (E⁻) populations, which were prepared from blood of healthy human donors as described by Mendes (*J. Immunol.* 111:860, 1973). Detection of mouse hybridoma antibodies binding to these cells was determined by indirect immunofluorescence. Cells incubated with culture supernatants were stained with a fluoresceinated goat-anti-mouse IgG (G/M FITC) (Meloy Laboratories, Springfield, VA; F/p=2.5) and the fluorescent antibody-coated cells were subsequently analyzed on the Cytofluorograf FC200/4800A (Ortho Instruments, Westwood, MA) as described in Example III. Hybridoma cultures containing antibodies reacting specifically with E⁺ lymphocytes (T cells) and/or thymocytes were selected and cloned twice by limiting dilution methods in the presence of feeder cells. Subsequently, the clones were transferred intraperitoneally by injecting 1×10^7 cells of a given clone (0.2 ml volume) into CAF₁ mice primed with 2,6,10,14-tetramethylpentadecane, sold by Aldrich Chemical Company under the name Pristine. The malignant ascites from these mice were then used to characterize lymphocytes as described below in Example II. The subject hybrid antibody OKT11 was demonstrated by standard techniques to be of IgG₁ subclass.

Example II

Characterization of OKT11 reactivity

A. Isolation of lymphocyte populations

Human peripheral blood mononuclear cells were isolated from healthy volunteer donors (ages 15–40) by Ficoll-Hypaque density gradient centrifugation (Pharmacia Fine Chemicals, Piscataway, NJ) following the technique of Boyum, *Scand. J. Clin. Lab. Invest.* 21 (Suppl. 97): 77, 1968. Unfractionated mononuclear cells were separated into surface Ig⁺ (B) and Ig⁻ (T plus Null) populations by Sephadex G-200 anti-F(ab')₂ column chromatography as previously described by Chess, *et al.*, *J. Immunol.* 113:1113 (1974). T cells were recovered by E rosetting the Ig⁻ population with 5% sheep erythrocytes (microbiological Associates, Bethesda, MD). The rosetted mixture was layered over Ficoll-Hypaque and the recovered E⁺ pellet treated with 0.155M NH₄Cl (10 ml per 10^8 cells). The T cell population so obtained was <2% EAC rosette positive and >95% E rosette positive as determined by standard methods. In addition, the non-rosetting Ig⁻ (Null cell) population was harvested from the Ficoll interface. This latter population was <5% E⁺ and ≤2% slg⁺. The surface Ig⁺ (B) population was obtained from the Sephadex G-200 column following elution with normal human gamma globulin as previously described. This population was >95% surface Ig⁺ and <5% E⁺.

B. Isolation of thymocytes

Normal human thymus gland was obtained from patients aged two months to 14 years undergoing corrective cardiac surgery. Freshly obtained portions of the thymus gland were immediately placed in 5% fetal calf serum in medium 199 (Gibco), finely minced with forceps and scissors, and subsequently made into single cell suspensions by being pressed through wire mesh. The cells were next layered over Ficoll-Hypaque and spun and washed as previously described in section A above. The thymocytes so obtained were >95% viable and ≥90% E rosette positive.

Example III

Cytofluorographic analysis and cell separation

Cytofluorographic analysis of monoclonal antibodies with all cell populations was performed by indirect immunofluorescence with fluorescein-conjugated goat anti-mouse IgG (G/M FITC) (Meloy Laboratories) utilizing a Cytofluorograf FC200/4800A (Ortho Instruments). In brief, 1×10^6 cells were treated with 0.15 ml OKT11 at a 1:500 dilution, incubated at 4°C for 30 minutes, and washed twice. The cells were then reacted with 0.15 ml of a 1:40 dilution G/M FITC at 4°C for 30 minutes, centrifuged, and washed three times. Cells were then analyzed on the Cytofluorograf, and the intensity of fluorescence per cell was recorded on a pulse height analyzer. A similar pattern of reactivity was seen at a dilution of 1:10,000, but further dilution caused loss of reactivity. Background staining was obtained by substituting a 0.15 ml aliquot of 1:500 ascites from a CAF₁ mouse intraperitoneally injected with a non-producing hybrid clone.

Brief description of the drawings

Figure 1 shows the fluorescence pattern obtained on the Cytofluorograf after reacting normal human thymocytes and E⁺ and E⁻ peripheral cells with OKT11 and other monoclonal antibodies at a 1:500 dilution

CH

and G/M FITC. Background fluorescence staining was obtained by incubating each population with a 1:500 dilution of ascitic fluid from a mouse injected with a non-producing clone.

The production of the hybridoma and the production and characterization of the resulting monoclonal antibody were conducted as described in the above Example. Although large quantities of the subject antibody were prepared by injecting the subject hybridoma intraperitoneally into mice and harvesting the malignant ascites, it is clearly contemplated that the hybridoma could be cultured *in vitro* by techniques well-known in the art and the antibody removed from the supernatant.

Table 1 shows the reactivity of OKT1, OKT3—6, and OKT8—11 with various human lymphoid cell populations. This pattern of reactivity is one test by which the subject antibody OKT11 may be detected and distinguished from other antibodies.

Figure 1 shows a representative fluorescence pattern obtained on the Cytofluorograf after reacting normal human thymocyte suspensions, and E⁻ and E⁺ peripheral cells with a 1:500 dilution of OKT11, OKT10, OKT8, and G/M FITC. In contrast to OKT1 and OKT3 T cell antigens (which increase when thymocytes mature to peripheral T cells), that of OKT11 antigen concomitantly decreases. The pattern of reactivity in Figure 1 is another test by which the subject antibody OKT11 may be detected and distinguished from other antibodies.

Table 2 shows the antigen phenotypes of human T lineage lymphocytes, using OKT11 and other monoclonal antibodies. This phenotype pattern provides a still further way to detect OKT11 antibody and distinguish it from other antibodies.

Table 3 shows the relationship between levels of peripheral T cells and T cell subsets and various disease states. These relationships may be used for diagnostic purposes (e.g., to detect acute infectious mononucleosis) by analyzing the blood sample of an individual suspected of having one of these disease states to determine the levels of T cells and T cell subsets. These relationships may also be used for therapeutic purposes where the cause of the disease state is an elevated level of a T cell subset (e.g., Type I acquired agammaglobulinemia). For therapeutic use, administration of the appropriate monoclonal antibody to a patient with an elevated T cell subset level will decrease or eliminate the excess. The relationships shown in Table 3 are a further way in which OKT11 antibody may be detected and distinguished from other antibodies.

Other monoclonal antibody producing hybridomas prepared by the present applicants (designated OKT1, OKT3, OKT4, and OKT5) are described and claimed in the following European patent applications Nos. 80300829.1, 80301356.4, 80301357.2, and 80303272.1. Still other monoclonal antibody producing hybridomas prepared by the present applicants (designated OKT6, OKT8, OKT9, and OKT10) are described and claimed in European patent applications Nos. 80304347.0, 80304348.8, 80304349.6 and 80304350.4. A further hybridoma prepared by the present applicants (designated OKM1) is described and claimed in a European patent application filed on even date herewith and entitled: Hybrid Cell Line for Producing Monoclonal Antibody to a Human Monocyte Antigen, Antibody, and Methods, and numbered 8130048.6. These applications are incorporated herein by reference.

According to the present invention there are provided a hybridoma capable of producing antibody against an antigen found on essentially all peripheral T cells and approximately 95% of normal human thymocytes, a method for producing this hybridoma, monoclonal antibody against an antigen found on essentially all normal human peripheral T cells and on approximately 95% of normal human thymocytes, methods for producing the antibody, compositions for treatment or diagnosis of disease or identification of T cell subclasses and methods of diagnosis employing this antibody.

TABLE 1
Cellular and tissue distribution of OKT antigens

5	Monoclonal antibody	Ig type	Peripheral blood (15)*		Spleen (4)	Bone marrow (6)	Thymus (15)
			E ⁺	E ⁻			
10	OKT1	IgG ₁	100**	0	29±9	<5	18±8
	OKT3	IgG _{2a}	100	0	31±8	<5	21±8
	OKT4	IgG _{2b}	64±4	0	16±3	<5	75±10
15	OKT5	IgG ₁	25±4	0	15±4	<5	77±8
	OKT6	IgG ₁	0	0	0	<5	68±8
20	OKT8	IgG _{2a}	34±3	0	17±4	<5	81±7
	OKT9	IgG ₁	0	0	0	<5	4±3
	OKT10	IgG ₁	5±3	13±4	10±5	16±4	96±4
25	OKT11**	IgG ₁	100	0	NT ⁺	NT	95±3

* number of samples examined

** mean ± S.D.

+ not determined

30 ++ five peripheral blood and thymus samples were examined

35

40

45

50

55

60

65

TABLE 2
Antigen phenotypes of human T lineage lymphocytes

	OKT1	OKT3	OKT4	OKT5	OKT6	OKT8	OKT9	OKT10	OKT11
Prothymocyte	-	-	-	-	-	-	-	+	-
Early Thymocyte	-(W)	-(W)	+	-	-	-	±	+	+
Common Thymocyte	-(W)	-(W)	+	+	+	+	±	+	+
Mature Thymocyte	+	+	+	-	-	-	-	+	+
Inducer (Helper)	+	+	-	+	-	+	-	+	+
Cytotoxic/Suppressor	+	+	-	+	-	-	-	-	+
W=very weak immunofluorescence									

TABLE 3
Peripheral mononuclear cell levels in disease states

Disease state	Mononuclear cell levels						
	OKT3 ⁺	OKT4 ⁺	OKT5	OKT8	OKT6	OKT11	OKM1
Primary Biliary Cirrhosis (2)	N	+	-	-	-	++	-
Multiple Sclerosis (advanced disease) (8)	-	N	-	-	-	-	+
Myasthenia Gravis (early untreated) (3)	O	O	O	O	O	-	+
Acute Graft vs Host (3)	O to -	-	O	+	+	+	-
Acquired Agammaglobulinemia Type I Type II		O	+				
Hyper IgE (4)	-	N	O to -	O to -	-	+	N
Acute Infectious Mononucleosis (4)*	+	O to -	++	++	O	++	-
Hodgkins Disease Stages I & II	N	N	N	N	O	O	N
Stages III & IV	-	N	N	N	O	O	++
Psoriasis (3/5)	N	+	+	N	O	N	N

N=within normal limits

O=absent

+=above normal

++=greatly above normal

-=below normal

---=greatly below normal

* these levels return to normal about one week prior to the disappearance of clinical symptoms.
The numbers in parentheses indicate the number of patients evaluated.

Although only a single hybridoma producing a single monoclonal antibody against a human thymocyte antigen is described, it is contemplated that the present invention encompasses all monoclonal antibodies exhibiting the characteristics described herein. It was determined that the subject antibody OKT11 belongs to the subclass IgG₁, which is one of four subclasses of murine IgG. These subclasses of immunoglobulin G differ from one another in the so-called "fixed" regions, although an antibody to a specific antigen will have a so-called "variable" region which is functionally identical regardless of which subclass of immunoglobulin G it belongs to. That is, a monoclonal antibody exhibiting the characteristic described herein may be of subclass IgG₁, IgG_{2a}, IgG_{2b}, or IgG₃, or of classes IgM, IgA, or other known Ig classes. The differences among these classes or subclasses will not affect the selectivity of the reaction pattern of the antibody, but may affect the further reaction of the antibody with other materials, such as (for example) complement or anti-mouse antibodies. Although the subject antibody is specifically IgG₁, it is contemplated that antibodies having the patterns of reactivity illustrated herein are included within the subject invention regardless of the immunoglobulin class or subclass to which they belong.

Further included within the subject invention are methods for preparing the monoclonal antibodies described above employing the hybridoma technique illustrated herein. Although only one example of a hybridoma is given herein, it is contemplated that one skilled in the art could follow the immunization, fusion, and selection methods provided herein and obtain other hybridomas capable of producing antibodies having the reactivity characteristics described herein. Since the individual hybridoma produced from a known mouse myeloma cell line and spleen cells from a known species of mouse cannot be further identified except by reference to the antibody produced by the hybridoma, it is contemplated that all hybridomas producing antibody having the reactivity characteristics described above are included within the subject invention, as are methods for making this antibody employing the hybridoma.

Further aspects of the invention are methods of diagnosis of disease employing the monoclonal antibody OKT11 or any other monoclonal antibody exhibiting the pattern of reactivity provided herein. The subject antibody may be employed to diagnose disease states as shown in Table 3. These techniques may be employed using OKT11 antibody alone or in combination with other antibodies (e.g., OKT3—OKT10). Patterns of reactivity with a panel of antibodies to T cells and T cell subsets will allow more precise detection of certain disease states than is possible using prior diagnostic methods.

Treatment of undesired states manifesting themselves as an excess of OKT11⁺ cells may be accomplished by administration of a therapeutically effective amount of OKT11 antibody to an individual in need of such treatment. By selective reaction with OKT11⁺ antigen, the effective amount of OKT11 antibody will reduce the excess of OKT11⁺ cells, thus ameliorating the effects of the excess. Diagnostic and therapeutic compositions comprising effective amounts of OKT11 antibody in admixture with diagnostically or pharmaceutically acceptable carriers, respectively, are also included within the present invention.

Since peripheral T cells are responsible for graft rejection, one example of a therapeutic use of OKT11 antibody is the administration to a graft recipient of an amount of OKT11 antibody effective to reduce or eliminate the graft rejection. In this way OKT11 antibody could be substituted for the anti-thymocyte globulin discussed above with a significant increase in specificity.

Claims

1. Mouse monoclonal antibody which:
 - i) reacts with essentially all normal human peripheral T cells;
 - ii) reacts with approximately 95% of normal human thymocytes; and
 - iii) does not react with any of the normal human cells in the group comprising B cells and Null cells.
2. Mouse monoclonal antibody according to claim 1 which is of class IgG.
3. Mouse monoclonal antibody according to claim 1 or claim 2, which exhibits the pattern of reactivity to normal human thymocytes, E⁺, and E⁻ cells shown in Figure 1.
4. Mouse monoclonal antibody according to any one of claims 1 to 3, which exhibits the pattern of reactivity to T lineage lymphocyte phenotypes as shown in Table 1.
5. Mouse monoclonal antibody according to any one of claims 1 to 4, which defines a T cell population (OKT 11⁺) which is lower than normal levels in myasthenia gravis and multiple sclerosis; higher than normal levels in acute graft versus host reaction, hyper IgE, acute infectious mononucleosis, and primary biliary cirrhosis; and completely absent in all stages of Hodgkins disease and psoriasis.
6. Mouse monoclonal antibody according to any one of claims 1 to 5, produced by a hybridoma formed by fusion of cells from a mouse myeloma line and spleen cells from a mouse previously immunised with leukemic cells from a human with T-ALL.
7. Mouse monoclonal antibody produced by hybridoma ATCC CRL 8027.
8. A hybridoma, which produces a mouse monoclonal antibody according to any one of claims 1 to 6, formed by fusion of spleen cells from a mouse previously immunized with leukemic cells from a human with T-ALL and cells from a mouse myeloma line.
9. Hybridoma ATCC CRL 8027 (OKT 11).
10. A method for preparing a mouse monoclonal antibody according to any one of claims 1 to 6, which comprises the steps of:

Although only a single hybridoma producing a single monoclonal antibody against a human thymocyte antigen is described, it is contemplated that the present invention encompasses all monoclonal antibodies exhibiting the characteristics described herein. It was determined that the subject antibody OKT11 belongs to the subclass IgG₁, which is one of four subclasses of murine IgG. These subclasses of immunoglobulin G differ from one another in the so-called "fixed" regions, although an antibody to a specific antigen will have a so-called "variable" region which is functionally identical regardless of which subclass of immunoglobulin G it belongs to. That is, a monoclonal antibody exhibiting the characteristic described herein may be of subclass IgG₁, IgG_{2a}, IgG_{2b}, or IgG₃, or of classes IgM, IgA, or other known Ig classes. The differences among these classes or subclasses will not affect the selectivity of the reaction pattern of the antibody, but may affect the further reaction of the antibody with other materials, such as (for example) complement or anti-mouse antibodies. Although the subject antibody is specifically IgG₁, it is contemplated that antibodies having the patterns of reactivity illustrated herein are included within the subject invention regardless of the immunoglobulin class or subclass to which they belong.

Further included within the subject invention are methods for preparing the monoclonal antibodies described above employing the hybridoma technique illustrated herein. Although only one example of a hybridoma is given herein, it is contemplated that one skilled in the art could follow the immunization, fusion, and selection methods provided herein and obtain other hybridomas capable of producing antibodies having the reactivity characteristics described herein. Since the individual hybridoma produced from a known mouse myeloma cell line and spleen cells from a known species of mouse cannot be further identified except by reference to the antibody produced by the hybridoma, it is contemplated that all hybridomas producing antibody having the reactivity characteristics described above are included within the subject invention, as are methods for making this antibody employing the hybridoma.

Further aspects of the invention are methods of diagnosis of disease employing the monoclonal antibody OKT11 or any other monoclonal antibody exhibiting the pattern of reactivity provided herein. The subject antibody may be employed to diagnose disease states as shown in Table 3. These techniques may be employed using OKT11 antibody alone or in combination with other antibodies (e.g., OKT3—OKT10). Patterns of reactivity with a panel of antibodies to T cells and T cell subsets will allow more precise detection of certain disease states than is possible using prior diagnostic methods.

Treatment of undesired states manifesting themselves as an excess of OKT11⁺ cells may be accomplished by administration of a therapeutically effective amount of OKT11 antibody to an individual in need of such treatment. By selective reaction with OKT11⁺ antigen, the effective amount of OKT11 antibody will reduce the excess of OKT11⁺ cells, thus ameliorating the effects of the excess. Diagnostic and therapeutic compositions comprising effective amounts of OKT11 antibody in admixture with diagnostically or pharmaceutically acceptable carriers, respectively, are also included within the present invention.

Since peripheral T cells are responsible for graft rejection, one example of a therapeutic use of OKT11 antibody is the administration to a graft recipient of an amount of OKT11 antibody effective to reduce or eliminate the graft rejection. In this way OKT11 antibody could be substituted for the anti-thymocyte globulin discussed above with a significant increase in specificity.

Claims

1. Mouse monoclonal antibody which:
 - i) reacts with essentially all normal human peripheral T cells;
 - ii) reacts with approximately 95% of normal human thymocytes; and
 - iii) does not react with any of the normal human cells in the group comprising B cells and Null cells.
2. Mouse monoclonal antibody according to claim 1 which is of class IgG.
3. Mouse monoclonal antibody according to claim 1 or claim 2, which exhibits the pattern of reactivity to normal human thymocytes, E⁺, and E⁻ cells shown in Figure 1.
4. Mouse monoclonal antibody according to any one of claims 1 to 3, which exhibits the pattern of reactivity to T lineage lymphocyte phenotypes as shown in Table 1.
5. Mouse monoclonal antibody according to any one of claims 1 to 4, which defines a T cell population (OKT 11⁺) which is lower than normal levels in myasthenia gravis and multiple sclerosis; higher than normal levels in acute graft versus host reaction, hyper IgE, acute infectious mononucleosis, and primary biliary cirrhosis; and completely absent in all stages of Hodgkins disease and psoriasis.
6. Mouse monoclonal antibody according to any one of claims 1 to 5, produced by a hybridoma formed by fusion of cells from a mouse myeloma line and spleen cells from a mouse previously immunised with leukemic cells from a human with T-ALL.
7. Mouse monoclonal antibody produced by hybridoma ATCC CRL 8027.
8. A hybridoma, which produces a mouse monoclonal antibody according to any one of claims 1 to 6, formed by fusion of spleen cells from a mouse previously immunized with leukemic cells from a human with T-ALL and cells from a mouse myeloma line.
9. Hybridoma ATCC CRL 8027 (OKT 11).
10. A method for preparing a mouse monoclonal antibody according to any one of claims 1 to 6, which comprises the steps of:



- i) immunizing mice with human leukemic T-ALL cells;
 - ii) removing the spleens from said mice and making a suspension of spleen cells;
 - iii) fusing said spleen cells with mouse myeloma cells in the presence of a fusion promoter;
 - iv) diluting and culturing the fused cells in separate wells in a medium which will not support the unfused myeloma cells;
 - v) evaluating the supernatant in each well containing a hybridoma for the presence of an antibody having the properties specified in any one of claims 1 to 6;
 - vi) selecting and cloning hybridomas producing the desired antibody; and
 - vii) recovering the antibody from the supernatant above said clones.
11. A method for preparing a mouse monoclonal antibody according to any one of claims 1 to 6, which comprises the steps of:
- i) immunizing mice with human leukemic T-ALL cells;
 - ii) removing the spleens from said mice and making a suspension of the spleen cells;
 - iii) fusing said spleen cells with mouse myeloma cells in the presence of a fusion promoter;
 - iv) diluting and culturing the fused cells in separate wells in a medium which will not support the unfused myeloma cells;
 - v) evaluating the supernatant in each well containing a hybridoma for the presence of an antibody having the properties specified in any one of claims 1 to 6;
 - vi) selecting and cloning hybridomas producing the desired antibody;
 - vii) transferring said clones intraperitoneally into mice; and
 - viii) harvesting the malignant ascites or serum from said mice.
12. A method for preparing a mouse monoclonal antibody, which comprises culturing the hybridoma ATCC CRL 8027 in a suitable medium and recovering the antibody from the supernatant above said hybridoma.
13. A method for preparing a mouse monoclonal antibody, which comprises injecting into a mouse the hybridoma ATCC CRL 8027 and recovering the antibody from the malignant ascites or serum of said mouse.
14. A diagnostic composition of matter for detection of OKT 11⁺ cell excess or deficiency comprising, in admixture with a diagnostically acceptable carrier, an amount of a mouse monoclonal antibody according to claim 5, claim 6 when dependent on claim 5, or claim 7 effective to detect OKT 11⁺ cell excess or deficiency.
15. A therapeutic composition of matter comprising, in admixture with a pharmaceutically acceptable carrier, an amount of a mouse monoclonal antibody according to claim 5, claim 6 when dependent on claim 5, or claim 7 effective to reduce the amount of OKT 11⁺ cells in an individual having an excess of said OKT 11⁺ cells.
16. A method for detection of deficiency or excess of OKT 11⁺ cells in an individual which comprises reacting a lymphocyte composition from said individual with a diagnostically-effective amount of a mouse monoclonal antibody according to claim 5, claim 6 when dependent on claim 5, or claim 7 or with a composition according to claim 14 and measuring the percentage of the population which reacts with said antibody.
17. Mouse monoclonal antibody according to claim 5, claim 6 when dependent on claim 5, or claim 7, or a composition according to claim 15, for use in the treatment of an OKT 11⁺ cell excess in an individual in need of such treatment.
18. Mouse monoclonal antibody according to any one of claims 1 to 7, or a composition according to claim 15, for use in the treatment of a graft recipient to reduce or eliminate rejection of said graft.
19. A method for preparing a composition according to claim 14 or claim 15, comprising mixing a diagnostically or pharmaceutically acceptable carrier with a diagnostically or pharmaceutically effective amount of a mouse monoclonal antibody according to claim 5, claim 6 when dependent on claim 5, or claim 7.

Patentansprüche

1. Monoklonaler Maus-Antikörper, welcher:
- i) mit im wesentlichen allen humanen peripheren T-Zellen reagiert;
 - ii) mit annähernd 95 % normalen humanen Thymocyten reagiert; und
 - iii) nicht mit irgendwelchen der normalen humanen Zellen in der B-Zellen und Null-Zellen umfassenden Gruppe reagiert.
2. Monoklonaler Maus-Antikörper nach Anspruch 1 der Klasse IgG.
3. Monoklonaler Maus-Antikörper nach Anspruch 1 oder 2, welcher das in Figur 1 dargestellte Reaktivitätsmuster gegenüber normalen humanen Thymocyten, E⁺- und E⁻-Zellen aufweist.
4. Monoklonaler Maus-Antikörper nach einem der Ansprüche 1 bis 3, welcher das in Tabelle 1 dargestellte Reaktivitätsmuster gegenüber T-Linie-Lymphocyte-Phenotypen aufweist.
5. Monoklonaler Maus-Antikörper nach einem der Ansprüche 1 bis 4, welcher eine T-Zellen-Population (OKT 11⁺) definiert, die niedriger liegt als normale Gehalte in Myasthenia gravis und in Multipler Sklerosis; höher liegt als normale Gehalte in akuter Implantat-gegen-Wirt-Reaktion, Hyper IgE, akuter infektiöser



20

Mononukleosis und primärer Gallenzirrhose; und völlig abwesend ist in allen Stadien der Hodgkins-Krankheit und von Psoriasis.

6. Monoklonaler Maus-Antikörper nach einem der Ansprüche 1 bis 5, welcher durch ein Hybridom gebildet wird, das durch Fusion von Zellen aus einer Maus-Myelom-Linie und von Milz-zellen von einer zuvor mit leukämischen Zellen von einem Menschen mit T-ALL immunisierten Maus gebildet ist.
7. Monoklonaler Maus-Antikörper, welcher von einem Hybridom ATCC CRL 8027 gebildet wird.
8. Ein Hybridom, welches einen monoklonalen Maus-Antikörper nach einem der Ansprüche 1 bis 6 produziert, gebildet durch Fusion von Milzzellen einer zuvor mit leukämischen Zellen von einem Menschen mit T-ALL immunisierten Maus und von Zellen aus einer Maus-Myelom-Linie.
9. Das Hybridom ATCC CRL 8027 (OKT 11).
10. Ein Verfahren zur Herstellung von monoklonalem Maus-Antikörper nach einem der Ansprüche 1 bis 6, umfassend die Stufen:
 - i) Immunisieren von Mäusen mit humanen leukämischen T-ALL-Zellen;
 - ii) Entfernen der Milz aus den genannten Mäusen und Bereiten einer Suspension von Milzzellen;
 - 15 iii) Fusion der genannten Milzzellen mit Maus-Myelom-Zellen in Gegenwart eines Fusionspromotors;
 - iv) Verdünnen und Vermehren der vereinigten Zellen in getrennten Vertiefungen in einem Medium, welches die nicht-vereinigten Myelom-Zellen nicht erhält;
 - v) Auswerten des Überstandes in jeder Vertiefung, die ein Hybridom enthält, hinsichtlich des Vorliegens eines Antikörpers mit den in einem der Ansprüche 1 bis 6 angegebenen Eigenschaften;
 - 20 vi) Auswählen und Klonen von Hybridomen, welche den gewünschten Antikörper bilden; und
 - vii) Gewinnen des Antikörpers aus dem Überstand über den genannten Klonen.
11. Ein Verfahren zur Herstellung eines monoklonalen Maus-Antikörpers nach einem der Ansprüche 1 bis 25 umfassend die Stufen:
 - i) Immunisieren von Mäusen mit humanen leukämischen T-ALL-Zellen;
 - ii) Entfernen der Milz aus den genannten Mäusen und Bereiten einer Suspension von Milzzellen;
 - iii) Fusion der genannten Milzzellen mit Maus-Myelom-Zellen in Gegenwart eines Fusionspromotors;
 - 30 iv) Verdünnen und Vermehren der vereinigten Zellen in getrennten Vertiefungen in einem Medium, welches die nicht-vereinigten Myelom-Zellen nicht erhält;
 - v) Auswerten des Überstandes in jeder Vertiefung, die ein Hybridom enthält, hinsichtlich des Vorliegens eines Antikörpers mit den in einem der Ansprüche 1 bis 6 angegebenen Eigenschaften;
 - 35 vi) Auswählen und Klonen von Hybridomen, welche den gewünschten Antikörper bilden;
 - vii) Überführen der genannten Klone auf intraperitonealem Wege in Mäuse; und
 - viii) Ernten der malignen Asciten oder von Serum aus den genannten Mäusen.
12. Ein Verfahren zur Herstellung von monoklonalem Maus-Antikörper, welches ein Vermehren des Hybridoms ATCC CRL 8027 in einem geeigneten Medium und das Gewinnen des Antikörpers aus dem Überstand über dem genannten Hybridom umfaßt.
- 40 13. Ein Verfahren zur Herstellung von monoklonalem Maus-Antikörper, welches ein Injizieren des Hybridoms ATCC CRL 8027 in eine Maus und das Gewinnen des Antikörpers aus den malignen Asciten oder aus dem Serum der genannten Maus umfaßt.
14. Eine diagnostische Zusammensetzung zur Feststellung eines OKT 11⁺-Zellen-Überschusses oder Mangels, umfassend, im Gemisch mit einem diagnostisch annehmbaren Träger, eine zur Feststellung eines OKT 11⁺-Zellen-Überschusses oder Mangels wirksame Menge eines monoklonalen Maus-Antikörpers nach Anspruch 5, Anspruch 6, falls abhängig von Anspruch 5, oder nach Anspruch 7.
15. Eine therapeutische Zusammensetzung, enthaltend, im Gemisch mit einem pharmazeutisch annehmbaren Träger, eine zur Verminderung der Menge an OKT 11⁺-Zellen in einem Individuum mit einem Überschuss an den genannten OKT 11⁺-Zellen wirksame Menge des monoklonalen Maus-Antikörpers nach Anspruch 5, Anspruch 6, falls abhängig von Anspruch 5, oder nach Anspruch 7.
- 50 16. Ein Verfahren zur Feststellung eines Mangels oder eines Überschusses an OKT 11⁺-Zellen in einem Individuum, umfassend ein Reagieren einer Lymphocyten-Zusammensetzung des genannten Individuums mit einer diagnostisch wirksamen Menge eines monoklonalen Maus-Antikörpers nach Anspruch 5, Anspruch 6, falls abhängig von Anspruch 5, oder Anspruch 7 oder mit einer Zusammensetzung nach Anspruch 14 und Messen des Prozentsatzes der Population, die mit dem genannten Antikörper reagiert.
17. Monoklonaler Maus-Antikörper nach Anspruch 5, Anspruch 6, wenn abhängig von Anspruch 5, oder nach Anspruch 7, oder Zusammensetzung nach Anspruch 15, zur Anwendung in der Behandlung eines OKT 11⁺-Zellen-Überschusses in einem Individuum, das eine solche Behandlung benötigt.
- 60 18. Monoklonaler Maus-Antikörper nach einem der Ansprüche 1 bis 7, oder Zusammensetzung nach Anspruch 15, zur Anwendung in der Behandlung eines Implantat-Empfängers zur Verminderung oder Vermeidung von Abstoßungsreaktionen zum genannten Implantat.
19. Ein Verfahren zur Herstellung einer Zusammensetzung nach Anspruch 14 oder 15, umfassend das Vermischen eines diagnostisch oder pharmazeutisch annehmbaren Trägers mit einer diagnostisch oder



pharmazeutisch wirksamen Menge eines monoklonalen Maus-Antikörpers nach Anspruch 5, Anspruch 6, wenn abhängig von Anspruch 5, oder nach Anspruch 7.

Revendications

1. Anticorps monoclonal de souris qui:
 - i) réagit avec essentiellement toutes les cellules T périphériques humaines normales;
 - ii) réagit avec environ 95% des thymocytes humains normaux; et
 - iii) ne réagit avec aucune des cellules humaines normales du groupe comprenant les cellules B et les cellules Null.
2. Anticorps monoclonal de souris selon la revendication 1, qui appartient à la fraction IgG.
3. Anticorps monoclonal de souris selon la revendication 1 ou la revendication 2, qui présente le profil de réactivité vis-à-vis des thymocytes humains normaux et des cellules E⁺ et E⁻ illustré par la figure 1.
4. Anticorps monoclonal de souris selon l'une quelconque des revendications 1 à 3, qui présente le profil de réactivité vis-à-vis des phénotypes des lymphocytes de la lignée T illustré par le tableau 1.
5. Anticorps monoclonal de souris selon l'une quelconque des revendications 1 à 4, qui détermine une population de cellules T (OKT 11⁺) qui est au-dessous des concentrations normales dans la myasthénie grave et la sclérose en plaques au-dessus des concentrations normales dans la réaction aiguë du greffon contre l'hôte, l'hyper IgE, la mononucléose infectieuse aiguë et la cirrhose biliaire primitive; et
6. Anticorps monoclonal de souris selon l'une quelconque des revendications 1 à 5, produit par un hybridome formé par fusion de cellules d'une lignée de myélome de souris et de cellules spléniques d'une souris préalablement immunisée par des cellules leucémiques d'un sujet humain atteint de leucémie lymphoblastique aiguë à cellules T.
7. Anticorps monoclonal de souris produit par l'hybridome ATCC CRL 8027.
8. Un hybridome qui produit un anticorps monoclonal de souris selon l'une quelconque des revendications 1 à 6, formé par fusion de cellules spléniques d'une souris préalablement immunisée avec des cellules leucémiques d'un sujet humain atteint de leucémie lymphoblastique aiguë à cellules T et de cellules d'une lignée de myélome de souris.
9. Hybridome ATCC CRL 8027 (OKT 11).
10. Un procédé pour la préparation d'un anticorps monoclonal de souris selon l'une quelconque des revendications 1 à 6, qui comprend les stades de:
 - i) immunisation de souris avec des cellules leucémiques d'un sujet humain atteint de leucémie lymphoblastique aiguë à cellules T;
 - ii) prélèvement des rates desdites souris et formation d'une suspension de cellules spléniques;
 - iii) fusion desdites cellules spléniques avec des cellules de myélome de souris en présence d'un promoteur de fusion;
 - iv) dilution et culture des cellules fusionnées dans les cupules séparées dans un milieu qui n'entretient pas les cellules de myélome non fusionnées;
 - v) évaluation du surnageant dans chaque cupule contenant un hybridome pour déterminer la présence d'un anticorps ayant les propriétés spécifiées dans l'une quelconque des revendications 1 à 6;
 - vi) sélection et clonage des hybridomes produisant l'anticorps désiré; et
 - vii) récupération de l'anticorps dans le surnageant au-dessus desdits clones.
11. Un procédé pour la préparation d'un anticorps monoclonal de souris selon l'une quelconque des revendications 1 à 6, qui comprend les stades de:
 - i) immunisation de souris avec des cellules leucémiques d'un sujet humain atteint de leucémie lymphoblastique aiguë à cellules T;
 - ii) prélèvement des rates desdites souris et formation d'une suspension des cellules spléniques;
 - iii) fusion desdites cellules spléniques avec des cellules de myélome de souris en présence d'un promoteur de fusion;
 - iv) dilution et culture des cellules fusionnées dans des cupules séparées dans un milieu qui n'entretient pas les cellules de myélome non fusionnées;
 - v) évaluation du surnageant dans chaque cupule contenant un hybridome pour déterminer la présence d'un anticorps ayant les propriétés spécifiées dans l'une quelconque des revendications 1 à 6;
 - vi) sélection et clonage des hybridomes produisant l'anticorps désiré;
 - vii) transfert intrapéritonéal desdits clones à des souris; et
 - viii) récolte du liquide d'ascite maligne ou du sérum desdites souris.
12. Un procédé pour la préparation d'un anticorps monoclonal de souris, qui comprend la culture de l'hybridome ATCC CRL 8027 dans un milieu approprié et la récupération de l'anticorps dans le surnageant au-dessus dudit hybridome.
13. Un procédé pour la préparation d'un anticorps monoclonal de souris, qui comprend l'injection à une souris de l'hybridome ATCC CRL 8027 et la récupération de l'anticorps à partir du liquide d'ascite maligne ou du sérum de ladite souris.



14. Une composition diagnostique pour la détection d'un excès ou d'un défaut de cellules OKT 11⁺ comprenant, en mélange avec un support convenant au diagnostic, une quantité d'un anticorps monoclonal de souris selon la revendication 5, la revendication 6 lorsqu'elle est subordonnée à la revendication 5, ou la revendication 7, efficace pour détecter un excès ou défaut de cellules OKT 11⁺.

5 15. Une composition thérapeutique comprenant, en mélange avec un support acceptable en pharmacie, une quantité d'un anticorps monoclonal de souris selon la revendication 5, la revendication 6 lorsqu'elle est subordonnée à la revendication 5, ou la revendication 7, efficace pour réduire la quantité des cellules OKT 11⁺ chez un sujet présentant un excès desdites cellules OKT 11⁺.

16. Un procédé pour la détection d'un excès ou d'un défaut de cellules OKT 11⁺ chez un sujet, qui comprend la réaction d'une composition de lymphocytes dudit sujet avec une quantité efficace pour le diagnostic d'un anticorps monoclonal de souris selon la revendication 5, la revendication 6 lorsqu'elle est subordonnée à la revendication 5, ou la revendication 7, ou avec une composition selon la revendication 14, et la mesure du pourcentage de la population qui réagit avec ledit anticorps.

17. Anticorps monoclonal de souris selon la revendication 5, la revendication 6 lorsqu'elle est subordonnée à la revendication 5, ou la revendication 7, ou une composition selon la revendication 15, pour l'emploi dans le traitement d'un excès de cellules OKT 11⁺ chez un sujet nécessitant un tel traitement.

18. Anticorps monoclonal de souris selon l'une quelconque des revendications 1 à 7, ou une composition selon la revendication 15, pour l'emploi dans le traitement d'un receveur de greffon pour réduire ou éliminer le rejet dudit greffon.

20 19. Un procédé pour préparer une composition selon la revendication 14 ou la revendication 15, comprenant le mélange d'un support acceptable pour le diagnostic ou acceptable en pharmacie avec une quantité efficace pour le diagnostic ou efficace en pharmacie d'un anticorps monoclonal de souris selon la revendication 5, la revendication 6 lorsqu'elle est subordonnée à la revendication 5, ou la revendication 7.

25

30

35

40

45

50

55

60

65

